What criteria should health systems use to evaluate enterprise AI platforms?

Health systems should evaluate enterprise AI platforms across four primary dimensions: integration architecture (whether a single integration serves all AI use cases or each workflow requires separate extraction builds); governance and compliance infrastructure (whether HIPAA compliance is enforced technically through interaction logging, BAA sub-processor coverage, and role-based access controls, or merely described in policy documents); clinical use case coverage and time to value (whether validated workflows are available at launch or must be custom-built); and vendor stability and partnership depth (model provider relationships, EHR integration certifications, and implementation track record with comparable health systems). Requirements across all four dimensions should be defined before vendor engagement begins.

How should a health system structure an AI platform pilot before enterprise commitment?

An effective enterprise AI platform pilot should deploy at least one production use case in the health system's actual environment — not a sandbox — and be structured to validate integration with existing clinical and operational systems, governance functionality including audit log retrieval and access control enforcement, and delivery of measurable value on an agreed timeline. The pilot should surface integration and compliance gaps before enterprise rollout, when the cost of discovering them is orders of magnitude lower. Health systems that skip the pilot in the interest of procurement speed consistently encounter integration and governance issues at scale that could have been identified and resolved during a structured pilot phase.

What is the most common mistake health systems make when selecting an AI platform?

The most common mistake is allowing vendor capabilities to define requirements rather than defining organizational requirements before vendor engagement. This leads health systems to evaluate platforms on the dimensions vendors present well — marketing demonstrations, feature lists, and vendor-curated case studies — rather than the dimensions that determine enterprise success: whether the platform can integrate with their specific EHR environment without repeated extraction builds, whether governance controls are technically enforced or only documented in policy, and whether the time to first production use case matches organizational capacity and financial timelines.

How Health Systems Evaluate Enterprise AI Platforms: A Framework for CIOs and CDOs

25 May 2026

6 minute read

Selecting an enterprise AI platform is among the highest-stakes infrastructure decisions a health system leadership team will make this decade. Unlike most enterprise software purchases, a core AI platform shapes every subsequent AI initiative — determining what use cases can be deployed, how quickly they can go live, what governance controls apply, and whether the organization ends up with a coherent or fragmented AI footprint five years from now. Health system CIOs, CDOs, and CMOs evaluating platform vendors today are operating in a market where nearly every vendor makes broadly similar claims about integration capability, clinical effectiveness, and speed to value. The evaluation frameworks that produce durable decisions are those that look past presentations and assess the structural dimensions that separate enterprise-ready AI platforms from sophisticated point solutions.

This is not primarily a technology evaluation. It is a governance, integration, and organizational architecture evaluation. The health systems that have deployed AI most successfully share a common characteristic: they defined what enterprise AI deployment needed to look like from a governance and integration standpoint before they engaged vendors, rather than allowing vendor capabilities to define requirements after the fact.

Integration Architecture: The Foundation Everything Else Depends On

The most consequential question a health system can ask any AI platform vendor is deceptively simple: does adding a new AI use case require a new integration build? In a mature enterprise AI platform, the answer is no. A single integration to the health system's EHR, data warehouse, claims environment, and operational systems creates a persistent data foundation that every AI workflow draws from without incremental IT lift. In a point solution architecture — or a platform that operates as a thin wrapper around individual applications — each new use case often requires a separate extraction build, a new HL7 or FHIR feed, and a new validation cycle. For a large health system deploying AI across clinical documentation, care coordination, revenue cycle, and population health simultaneously, the cumulative IT overhead of the latter approach is not a minor inefficiency. It is an organizational constraint that will limit AI deployment velocity for years. Health system CIOs should ask vendors to map, concretely, how their platform connects to Epic or Oracle Health, how that integration is maintained across EHR version updates, and what the process is for adding a new data source when a new use case requires it.

Governance and Compliance: Infrastructure, Not Policy

HIPAA compliance for enterprise AI is not a documentation exercise. A health system deploying AI across 10,000 clinicians and staff generates hundreds of thousands of AI interactions involving patient data every week. Governing those interactions through policy documents and periodic manual sampling is not a governance program — it is an aspiration that will fail the first time an audit, a patient safety event, or a regulatory inquiry requires a specific accounting of what the AI did with a specific patient's information.

A genuinely governed enterprise AI platform enforces compliance technically, not administratively. This means comprehensive interaction logging — capturing every AI input, every model output, the model version active at the time, and the user or workflow that triggered the interaction — in a structured format queryable without an IT project. It means BAA coverage that extends to sub-processors, including the foundation model providers that underpin the platform's clinical capabilities. And it means role-based access controls that are technically enforced, not merely documented in a user policy. Health system CDOs should ask vendors for a concrete demonstration of what an audit record looks like for a specific AI interaction, how quickly it can be retrieved, and whether retrieval requires vendor assistance. Organizations operating under value-based contracts face an additional governance dimension: the ability to trace quality measure performance and shared savings results back to specific AI-assisted interventions, so that payer audits can be answered with evidence rather than approximations.

Clinical Use Case Coverage and Time to Value

Enterprise AI platforms differ significantly in the ratio of pre-validated solutions to build-your-own capability. A platform that offers a robust library of validated clinical and operational AI workflows — ambient documentation, prior authorization drafting, risk stratification, care gap closure, clinical inbox management — allows a health system to achieve demonstrable value within 90 days of deployment. A platform that provides primarily infrastructure tooling and an AI development environment may offer greater long-term customization, but the time to first production use case is typically measured in quarters, not weeks, and requires significant internal technical resources to realize.

Neither model is universally superior. Health systems with mature clinical informatics teams and a defined roadmap of proprietary AI use cases may appropriately prioritize platform flexibility. Health systems seeking near-term ROI — or facing the financial pressure that an expected $1 trillion in federal healthcare funding reductions will create through 2034 — should weight pre-validated solution coverage heavily in their evaluation. The critical evaluation discipline is to match vendor capability honestly to organizational capacity rather than assuming that a capable internal team will have the bandwidth to build what the vendor does not provide.

Vendor Stability and Strategic Partnership Depth

A health system entering a multi-year enterprise AI platform relationship is not acquiring software alone. It is acquiring a technical partner whose roadmap decisions, model provider relationships, and organizational trajectory will materially affect what AI capabilities the health system can access over time. The enterprise AI market is consolidating rapidly, and the vendors best positioned to sustain long-term enterprise relationships are those with strategic partnerships with leading foundation model providers — giving them preferential access to frontier model capabilities — established EHR integration certifications, and the financial runway to support multi-year deployment commitments. Health system procurement teams should ask for clear documentation of a vendor's model provider partnerships, EHR certification status, and customer implementation track record. Reference checks with health system customers of comparable size and complexity are more informative than any vendor-provided case study.

A Structured Evaluation Framework

The most effective enterprise AI platform evaluations define requirements across four dimensions before vendor engagement begins: integration architecture requirements (what systems the platform must connect to and how); governance requirements (what audit, access control, and compliance capabilities must be technically enforced, not just described in vendor documentation); use case requirements (which workflows must be available at launch versus within the first 12 months); and organizational support requirements (what implementation, change management, and ongoing optimization the vendor must provide). Vendors are then assessed against those requirements, with proof of capability demonstrated through reference checks with current health system customers and through a structured pilot that deploys an actual use case in the health system's own environment.

The pilot is not optional. An enterprise AI platform's true integration complexity, governance functionality, and time-to-value characteristics become visible in a real deployment context in ways that no presentation can replicate. A pilot structured to validate that the platform integrates with existing systems, operates within defined governance parameters, and delivers measurable value on an agreed timeline is the single most reliable signal available before a full enterprise commitment. Health systems that skip the pilot in the interest of procurement speed typically discover integration and governance gaps at the point of enterprise rollout — when the cost of discovering them is orders of magnitude higher.

To learn how Skovos's governed enterprise platform addresses each of these evaluation dimensions, and to walk through the evaluation against your organization's own requirements, contact our team.